Working Groups

Medicinal chemistry, also termed medical chemistry, researches chemical properties of new and old agents and develops innovative therapy options. Ralph Holl’s research group focuses on manufacturing and/or designing new inhibitors: small molecules that specifically target metabolic pathways in ...

Alexander Titz’s research group focuses on biofilms, which is a slimy layer that bacteria produce to physically protect themselves against the immune system and against antibiotics. For example, Pseudomonas aeruginosa, a dreaded hospital pathogen, is a member of this group of bacteria and uses ...

A Microscopy Unit was established at the Heidelberg Partner Site for research groups from the research field “Hepatitis” and other research fields including “Emerging Infections” in particular. The Microscopy Unit enables research groups to conduct their analyses and investigate live cells and ...

The working group deals with the genetic analysis of tuberculosis pathogens. It uses the latest techniques of DNA sequencing (next generation sequencing) to determine the distribution of individual TB strains based on gene sequences. The molecular epidemiological data are combined with traditional ...

The research group led by Dr Angelika Riemer has set itself the goal of developing a functional therapeutic vaccine against human papillomavirus (HPV) infections and against HPV-induced tumours. While prophylactic vaccines induce the production of antibodies to prevent an infection with the pathogen ...

Mosquitoes are transmitters of numerous viruses that are pathogenic to humans. Besides the known local species, new types of mosquitoes have been imported into Germany over the past few years. In order prepare for the potential formation of colonies of these new types of mosquitoes and the ...

The working group runs a platform to evaluate the efficacy of new drugs and to select optimal treatment options for tuberculosis patients. In vitro test systems are available for preclinical testing, which are used to test the activity of substances against tuberculosis-causing mycobacteria. An ...

According to the World Health Organisation (WHO), the global emergence of antibiotic resistance is one of the greatest threats to human health. In light of this, it is of utmost importance that new agents and target sites for drugs are identified. Once new lead compounds have been identified, the ...

Dr. Ute Klarmann-Schulz’s research group’s objective is to support the transition of new anti-infective agent candidates from preclinical into clinical phases of development, and to ensure that the first clinical trials run as smoothly as possible. In the field of preclinical development, the junior ...

While there are treatment options for the immunodeficiency syndrome AIDS today, there is still not a cure. This is mainly due to the fact some of the human immunodeficiency viruses invade the genome of the host, where they cannot be attacked. Therapeutic agents can only destroy the free viruses in ...